Re-Evaluating Duration of Therapy in Advanced Non–Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?
- 10 July 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (20) , 3268-3270
- https://doi.org/10.1200/jco.2009.22.4345
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized TrialsJournal of Clinical Oncology, 2009
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of TherapyJournal of Thoracic Oncology, 2009
- Recommendations for the assessment of progression in randomised cancer treatment trialsEuropean Journal Of Cancer, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 2008
- Endpoints for Assessing Drug Activity in Clinical TrialsThe Oncologist, 2008
- Duration of First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent TherapiesJournal of Clinical Oncology, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995